Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/09/2021 06/10/2021 06/11/2021 06/14/2021 06/15/2021 Date
82.71(c) 86.75(c) 86(c) 86.12(c) 83.14 Last
1 543 052 1 405 109 1 126 851 793 180 1 281 270 Volume
+3.85% +4.88% -0.86% +0.14% -3.46% Change
More quotes
Financials (USD)
Sales 2021 640 M - -
Net income 2021 -568 M - -
Net cash position 2021 393 M - -
P/E ratio 2021 -12,3x
Yield 2021 -
Sales 2022 856 M - -
Net income 2022 -372 M - -
Net cash position 2022 187 M - -
P/E ratio 2022 -19,6x
Yield 2022 -
Capitalization 6 870 M 6 870 M -
EV / Sales 2021 10,1x
EV / Sales 2022 7,81x
Nbr of Employees 866
Free-Float 95,2%
More Financials
Company
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug... 
Sector
Biotechnology & Medical Research
Calendar
06/16 | 10:30amPresentation
More about the company
Ratings of Sarepta Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SAREPTA THERAPEUTICS, INC.
07:05aSAREPTA THERAPEUTICS  : BTIG Starts Sarepta Therapeutics at Buy With $110 Price ..
MT
06/03SAREPTA THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holder..
AQ
06/03Sarepta Therapeutics to Present at Upcoming Investor Conferences
GL
05/28Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
05/18Walmart, Sarepta rise; Chevron, D.R. Horton fall
AQ
05/18SECTOR UPDATE : Health Care Stocks Adding to Small Afternoon Gains
MT
05/18SECTOR UPDATE : Health Care Stocks Posting Modest Gains
MT
05/18SAREPTA THERAPEUTICS'  : Investigational Gene Therapy SRP-9001 Demonstrates Posi..
MT
05/18SAREPTA THERAPEUTICS  : Results from the first 11 participants enrolled in Study..
PU
05/18SAREPTA THERAPEUTICS, INC.  : Regulation FD Disclosure, Financial Statements and..
AQ
05/18SAREPTA THERAPEUTICS  : Clinical Update Micro-dystrophin SRP-9001-103_05.18.2021
PU
05/18Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duche..
GL
05/17Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (E..
GL
05/11SAREPTA THERAPEUTICS  : ASGCT 2021_Rodino-Klapac et al._Safety Exp & Funct Outco..
PU
05/06SAREPTA THERAPEUTICS  : ASGCT 2021_Mendell et al._A RCT of rAAVrh74.MHCK7.micro-..
PU
More news
News in other languages on SAREPTA THERAPEUTICS, INC.
2020ROCHE : Sarepta revendique des progrès contre la myopathie de Duchenne
2020Bourse Zurich: la prudence de retour pour la dernière séance de la semaine
2020ROCHE  : procédure accélérée pour une molécule de Sarepta
2020ROCHE : statut de revue prioritaire pour un médicament contre la DMD
2019EN DIRECT DES MARCHES : Sanofi, Renault, Virbac, Marie Brizard, Recylex, Créd..
More news
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
More recommendations
Chart SAREPTA THERAPEUTICS, INC.
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 121,94 $
Last Close Price 86,12 $
Spread / Highest target 128%
Spread / Average Target 41,6%
Spread / Lowest Target -16,4%
EPS Revisions
Managers and Directors
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
Ian M. Estepan Executive VP, Chief Financial & Accounting Officer
M. Kathleen Behrens Wilsey Chairman
Gilmore O’Neill Chief Medical Officer & Executive Vice President
Louise Rodino-Klapac Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS, INC.-49.49%6 870
GILEAD SCIENCES, INC.16.98%85 472
WUXI APPTEC CO., LTD.30.07%66 801
REGENERON PHARMACEUTICALS9.45%54 755
BIONTECH SE170.58%53 275
VERTEX PHARMACEUTICALS-17.58%50 427